Abstract: Intraocular extended-release drugs have the characteristics of long administration interval and high patient compliance. In recent years,  new anti-vascular endothelial growth factor extended-release devices, such as Port Delivery System with Ranibizumab, have entered phase III clinical trials for treatment of age-related macular degeneration; the indications for dexamethasone extended-release formulations (Ozurdex, Dexycu, Dextenza) have been further expanded and have been used for retinal vein obstruction, non-infectious uveitis, and diabetic macular edema treatment;  extended-release drops for the treatment of endophthalmitis, glaucoma, and cystine disease are expected to to improve the quality of patient care by replacing traditional eye drops. (Int Rev Ophthalmol, 2023, 47: 218-222)

Key words: drug sustained-release system, dexamethasone, anti-vascular endothelial growth factor, eye drops